Evotec's Turnaround Math: Can €75 Million in Savings Outpace a €100 Million Restructuring Bill?

Evotec's turnaround hinges on €75M savings by 2027, but restructuring costs hit €98.9M. H1 revenue fell 19.2%, EBITDA loss widened.

The arithmetic facing Evotec shareholders has become brutally simple. The Hamburg-based drug discovery specialist needs its Horizon cost-cutting program to deliver roughly €75 million in annual savings by the end of 2027 — but the restructuring itself has already consumed €98.9 million, and the bill is still climbing. That gap between upfront expense and promised payoff is now the central tension in the company's investment case.

The stakes were laid bare in the half-year results published on August 13. Revenue fell to €300.1 million, a 19.2 percent decline year-on-year, while adjusted EBITDA swung to a loss of €42.7 million from a loss of just €1.9 million in the prior-year period. Management has nonetheless reaffirmed its full-year guidance — revenue between €570 million and €610 million, with adjusted EBITDA landing anywhere from minus €70 million to minus €105 million.

A Balance Sheet Bought Some Breathing Room

Evotec has taken steps to ensure the turnaround isn't starved of capital. In May, the company placed convertible bonds worth €116.1 million, and it monetized its stake in Tubulis for roughly $100 million. These moves were designed to fund the transition period without forcing the company into emergency capital raises — a scenario that would have compounded the pain for existing shareholders.

The market, however, remains unconvinced. The stock has shed 5.2 percent since the guidance reaffirmation two weeks ago, and the shares closed Friday at €3.37, down 0.8 percent on the day. That leaves the equity just 5.5 percent above its 52-week low of €3.19 and roughly 38 percent below where it started the year. On August 21, the shares touched €3.33, a fresh ten-year trough.

Growth Pockets Offer a Counter-Narrative

Not every segment is bleeding. Net revenues in the Discovery & Precision Discovery (D&PD) unit climbed 28 percent in the first half, excluding strategic partnerships, and Just-Evotec Biologics is running at high capacity utilization. These bright spots suggest the operational erosion is concentrated in partnership-driven businesses rather than the core service model.

The early-August collaboration with Odyssey Therapeutics, focused on AI-powered research into autoimmune and inflammatory diseases, adds another constructive data point. It demonstrates that Evotec can still attract new partners even as its financial results deteriorate — a signal that the franchise retains commercial appeal. If that momentum persists, the current market capitalization of roughly €601 million may look overly pessimistic.

Boardroom Turbulence Adds a Wrinkle

The company's governance has also come under scrutiny. Camilla Macapili Languille, an independent member of the Audit & Compliance Committee since June 2022, resigned about three weeks ago. The departure has raised questions about whether the supervisory board is adequately staffed during such a delicate transition — though the market's muted reaction suggests investors are more focused on the operating numbers than personnel matters.

The Second-Half Test

The July profit warning that slashed the annual outlook has already inflicted lasting damage on credibility, and the shares have yet to recover from that blow. The critical question now is whether the second half delivers the stabilization that management's reaffirmed guidance implies. If revenue keeps sliding and the Horizon savings arrive slower than promised, the EBITDA target range could prove as fragile as the previous one.

The next checkpoint arrives with third-quarter figures, when investors will see whether the measures initiated over the summer are actually taking hold. With the stock trading barely above its recent lows, there is little room for disappointment — and everything to play for if the cost savings finally start showing up in the numbers.